Research Report Sees Mexico Cardiac Rhythm Device Market Growth Through 2036, Abbott Cited
What happened
A new market outlook published via GlobeNewswire projects the Mexico cardiac rhythm management devices market through 2036, covering revenue, volume, and pricing trends alongside competitive positioning. The report lists Abbott (ABT) among the key competitors tracked in the segment. The publisher frames the long-horizon outlook with a positive tone, citing demand for pacemakers, defibrillators, and related monitoring devices across the Mexican healthcare market.
The QL Read
The report lands while ABT's QuantLogix composite sits at 31/100 (Underweight) and the stock trades at $103.49, down 0.08%. In a soft tape (S&P 500 -0.75%, VIX up 6.26% to 16.13, XLV lagging at -0.64%), a long-dated international TAM note is unlikely to move the engine's current bearish-leaning read.